.jpg?w=340&itok=JWjgoweu "IPT discussed in technical publications."){kind=icon}
Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to si...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Early protocol assessment for increased patient centricity
In this article in Applied Clinical Trials, Emily Mitchell, Executive Director, eClinical Development and Delivery, outlines how thorough assessment of protocols, whether for DCTs or hybrid clinical trials that incorporate decentralised components, can ensure that studies are designed to minimise patient burden while optimising opportunities to leverage data on a wider scale.
-
Centred on decentralised trials: Q&A with Harpreet Gill
In this article on Pharmaceutical Executive’s website, Harpreet Gill discusses how DCTs can transform clinical trials and improve the patient experience.
-
Patient-first technology development increasing patient centricity
This article by Carrye Nibblelink, Executive Director, Decentralised Clinical Trial Solutions in the Journal of mHealth explores how the ICON Digital Platform engages patients throughout their clinical trial journey.
Copyright 2023 The Journal of mHealth (Simidics Ltd)
-
Regulatory considerations in technology for decentralised clinical trials
This article in the Journal of mHealth explores the guidance regulators have provided for diversity and inclusion in clinical trials, privacy considerations and endpoint selection, and is authored by Jo Hulbert, Executive Director, Global Regulatory Clinical Services with contributions from Arwa Shurrab, Senior Director, Global Regulatory Affairs and Priti Prasad, Senior Manager, Global Regulatory Affairs.
Copyright 2023 The Journal of mHealth (Simedics Ltd)
-
Trial blazing
Harpreet Gill, Vice President, Decentralised Clinical Trials at ICON reflects on the progress that has been made in decentralised and hybrid clinical trials in the last number of years in this article in PharmaTimes.
January/February PharmaTimes
-
Boon and bane: dodging participant burden in decentralised clinical trials
As DCT adoption increases, Harpreet Gill, Head of Decentralised Clinical Trial Solutions at ICON contributes to this piece in Clinical Trials Arena which looks at how sponsors and CROs must mind the risk of adding patient burden while designing decentralised trials.
Verdict Media Limited 2022
-
Expert Q&A: The impact of the clinical trial liaison function
Expert Q&A: The impact of the clinical trial liaison function
The clinical trial liaison (CTL) function was first introduced in 2014 to help sponsors differentiate themselves from the competition by driving recruitment success in clinical trials.
FirstWord spoke with Elizabeth Pash, Senior Director of Global Site Engagement Operations at ICON, to find out exactly what this relatively new role involves, its value in developing and delivering optimal clinical trials and how it is set to evolve in future.
Summary points from the interview:
- In the competitive world of pharmaceutical research, sponsors can differentiate themselves by driving recruitment success in clinical trials.
- The CTL role was introduced in 2014 to bring doctorate-trained clinical research professionals into the clinical trial process to support site identification, activation and recruitment, ensuring optimal productivity of clinical trials.
- While CTLs and clinical research associates (CRAs) are both considered protocol experts and build relationships with sites, CTLs focus on the scientific aspects of a protocol rather than the eligibility criteria and schedule of assessments.
- At ICON, CTLs have contributed to a 20% boost in the targeted recruitment rate and helped approximately 70% of sites achieve their baseline recruitment goals. In the past five years, they have also helped sponsors bring nine new compounds to market and receive two new indication approvals for already-approved medications.
- As more clinical trials begin to incorporate more decentralised approaches, the need for roles like CTLs is set to steadily increase across the industry.
- Potential is increasing for CTLs to establish partnerships earlier with sponsors, supporting trial and protocol design, conducting targeted investigator interviews and applying the information in the early stages of clinical development.
[Subscription is required to view the entire interview]
-
.jpg?w=545&itok=gEN1Uum_ "IPT discussed in technical publications.")
Providing support throughout the patient journey
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. Laney Preheim outlines how they can best be implemented.
This article is taken fromInnovations in Pharmaceutical Technology, October 2022, pages 34-36 . Samedan Ltd
-
What Biotech and Pharma need to consider about decentralised trials
Discuss key considerations when implementing decentralised clinical trials, in addition to the success factors that lead to more patient-centric trials and increased patient recruitment, engagement and retention.
-
The surge of digital health technologies modernising clinical research
Dr. Isaac R. Rodriguez-Chavez outlines the key considerations when developing digital health technologies.
